MedTrace Logo

Early Detection of Gastric Cancer Using Plasma Cell-free DNA Fragmentomics

NCT05269056 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2022-06-02

No results posted yet for this study

Summary

The purpose of this study is to enable non-invasive early detection of gastric cancer in high-risk populations through the establishment of a multimodal machine learning model using plasma cell-free DNA fragmentomics. Plasma cell-free DNA from early stage gastric cancer patients and healthy individuals will be subjected to whole-genome sequencing. Features, such as cell-free DNA fragmentation, copy number variations and microbiome, will be assessed to generate this model.

Conditions

  • Early Gastric Cancer

Sponsors & Collaborators

  • Nanjing Geneseeq Technology Inc.

    collaborator INDUSTRY

  • Zhejiang Cancer Hospital

    lead OTHER

Principal Investigators

  • Xiangdong Cheng, MD, PhD · Zhejiang Cancer Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2022-11-01
Completion
2023-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05269056 on ClinicalTrials.gov